• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

确定小型猪动脉粥样硬化斑块中卟吩姆钠的最佳剂量。

Determining the optimal dose of Photofrin in miniswine atherosclerotic plaque.

作者信息

Hsiang Y N, Fragoso M, Tsang V, Schreiber W E

机构信息

Department of Surgery, University of British Columbia, Vancouver, Canada.

出版信息

Photochem Photobiol. 1993 Mar;57(3):518-25. doi: 10.1111/j.1751-1097.1993.tb02329.x.

DOI:10.1111/j.1751-1097.1993.tb02329.x
PMID:8475189
Abstract

The purpose of this study was to determine the lowest dose of Photofrin (P) that would produce a 3:1 or greater ratio between atherosclerotic (AS) and control arterial walls. Aortoiliac AS was created in 24 Yucatan miniswine by a combination of balloon endothelial injury and 2% cholesterol and 15% lard diet for 7 weeks. Arteriography was then performed to demonstrate AS lesions. Following this, swine were given intravenously P in one of the following single dosages: 2.5, 1.0 or 0.5 mg/kg. Twenty-four hours later, swine were sacrificed and aortoiliac and control carotid artery segments removed and photographed with ultraviolet light to differentiate fluorescent from nonfluorescent areas. Arterial specimens were submitted for histologic analysis and chemical extraction for determination of fluorescence using a spectrofluorometer. Tissue concentration (ng/g tissue) of P from AS vessels were: Group I, 130.4 +/- 82.7; Group II, 10.0 +/- 1.2; and Group III, 9.1 +/- 0.6, respectively (P < 0.05). Ratios of P concentration in AS: control vessels were: Group I, 8.1 +/- 13.7; Group II, 1.1 +/- 0.2; and Group III, 0.9 +/- 0.1, respectively (P < 0.05). These results demonstrated that a P dose of 2.5 mg/kg provided at least a 3:1 ratio between AS: control artery wall.

摘要

本研究的目的是确定能使动脉粥样硬化(AS)与对照动脉壁之间产生3:1或更高比例的光卟啉(P)的最低剂量。通过球囊内皮损伤、2%胆固醇和15%猪油饮食联合作用7周,在24只尤卡坦小型猪中诱发腹主动脉髂动脉AS。然后进行动脉造影以显示AS病变。在此之后,给猪静脉注射以下单一剂量之一的P:2.5、1.0或0.5mg/kg。24小时后,处死猪,取出腹主动脉髂动脉和对照颈动脉节段,用紫外光拍照以区分荧光区和非荧光区。将动脉标本送去进行组织学分析和化学提取,用荧光分光光度计测定荧光。AS血管中P的组织浓度(ng/g组织)分别为:第一组,130.4±82.7;第二组,10.0±1.2;第三组,9.1±0.6(P<0.05)。AS与对照血管中P浓度的比值分别为:第一组,8.1±13.7;第二组,1.1±0.2;第三组,0.9±0.1(P<0.05)。这些结果表明,2.5mg/kg的P剂量能使AS与对照动脉壁之间至少达到3:1的比例。

相似文献

1
Determining the optimal dose of Photofrin in miniswine atherosclerotic plaque.确定小型猪动脉粥样硬化斑块中卟吩姆钠的最佳剂量。
Photochem Photobiol. 1993 Mar;57(3):518-25. doi: 10.1111/j.1751-1097.1993.tb02329.x.
2
Assessing Photofrin uptake in atherosclerosis with a fluorescent probe: comparison with photography and tissue measurements.使用荧光探针评估动脉粥样硬化中卟吩姆钠的摄取:与摄影及组织测量结果的比较
Lasers Surg Med. 1993;13(3):271-8. doi: 10.1002/lsm.1900130303.
3
Photodynamic therapy for atherosclerotic stenoses in Yucatan miniswine.
Can J Surg. 1994 Apr;37(2):148-52.
4
Intraluminal endothelium-covered bridges in chronic fat-fed balloon-injured Yucatan miniswine.慢性高脂喂养球囊损伤尤卡坦小型猪体内的腔内内皮覆盖桥
J Invest Surg. 1994 Nov-Dec;7(6):541-50. doi: 10.3109/08941939409015371.
5
Determining light dose for photodynamic therapy of atherosclerotic lesions in the Yucatan miniswine.
J Endovasc Surg. 1995 Nov;2(4):365-71. doi: 10.1583/1074-6218(1995)002<0365:DLDFPT>2.0.CO;2.
6
In vitro and in vivo uptake of benzoporphyrin derivative into human and miniswine atherosclerotic plaque.苯并卟啉衍生物在体外和体内对人和小型猪动脉粥样硬化斑块的摄取情况。
Photochem Photobiol. 1993 Apr;57(4):670-4. doi: 10.1111/j.1751-1097.1993.tb02935.x.
7
In vivo photosensitizer-enhanced laser angioplasty in atherosclerotic Yucatan miniswine.在动脉粥样硬化的尤卡坦小型猪体内进行光敏剂增强激光血管成形术。
J Clin Laser Med Surg. 1990 Jun;8(3):59-61. doi: 10.1089/clm.1990.8.59.
8
Gadofluorine-enhanced magnetic resonance imaging of carotid atherosclerosis in Yucatan miniswine.钆弗罗胺增强磁共振成像对尤卡坦小型猪颈动脉粥样硬化的研究
Invest Radiol. 2006 Mar;41(3):299-304. doi: 10.1097/01.rli.0000188362.12555.62.
9
Longer term assessment of photodynamic therapy for intimal hyperplasia: a pilot study.
J Photochem Photobiol B. 2004 Feb 20;73(3):141-7. doi: 10.1016/j.jphotobiol.2003.10.004.
10
Dosage and timing of Photofrin for photodynamic therapy of intimal hyperplasia.
Cardiovasc Surg. 1995 Oct;3(5):489-94. doi: 10.1016/0967-2109(95)94447-5.

引用本文的文献

1
Photodynamic Therapy for Atherosclerosis: Past, Present, and Future.动脉粥样硬化的光动力疗法:过去、现在与未来。
Pharmaceutics. 2024 May 29;16(6):729. doi: 10.3390/pharmaceutics16060729.
2
Application of Photodynamic Therapy in Cardiology.光动力疗法在心脏病学中的应用。
Int J Mol Sci. 2024 Mar 11;25(6):3206. doi: 10.3390/ijms25063206.
3
Photodynamic Therapy and Cardiovascular Diseases.光动力疗法与心血管疾病
Int J Mol Sci. 2024 Mar 4;25(5):2974. doi: 10.3390/ijms25052974.
4
Therapeutic Strategies and Chemoprevention of Atherosclerosis: What Do We Know and Where Do We Go?动脉粥样硬化的治疗策略与化学预防:我们知道什么以及将何去何从?
Pharmaceutics. 2022 Mar 28;14(4):722. doi: 10.3390/pharmaceutics14040722.
5
Inhibitory Effect of Photodynamic Therapy with Indocyanine Green on Rat Smooth Muscle Cells.吲哚菁绿光动力疗法对大鼠平滑肌细胞的抑制作用
Acta Cardiol Sin. 2019 Jan;35(1):65-74. doi: 10.6515/ACS.201901_35(1).20180731A.